Literature DB >> 6173750

Familial dysalbuminemic hyperthyroxinemia: a syndrome that can be confused with thyrotoxicosis.

M Ruiz, R Rajatanavin, R A Young, C Taylor, R Brown, L E Braverman, S H Ingbar.   

Abstract

We investigated 15 euthyroid patients from eight families with a recently recognized syndrome, familial dysalbuminemic hyperthyroxinemia (FDH), that could be mistaken for thyrotoxicosis. The syndrome is characterized by elevations in serum thyroxine and the free-thyroxine index (FT4l), which are due to an abnormal serum albumin that preferentially binds thyroxine. This albumin has an abnormal binding site with a much greater affinity for thyroxine (relative to its affinity for triiodothyronine) than that of the hormone-binding site on thyroxine-binding globulin. Results of thyrotropin-releasing hormone and thyroid-suppression tests, as well as direct measurements of the free-thyroxine concentration by equilibrium dialysis, are normal in these patients, although the serum triiodothyronine concentration may be slightly elevated. Although its prevalence is uncertain, FDH may be more common than suspected; we have seen 26 cases within the past year.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6173750     DOI: 10.1056/NEJM198203183061103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

1.  Familial dysalbuminemic hyperthyroxinemia in a 4-year-old girl with hyperactivity, palpitations and advanced dental age: how gold standard assays may be misleading.

Authors:  Abha Choudhary; Chutintorn Sriphrapradang; Samuel Refetoff; Zoltan Antal
Journal:  J Pediatr Endocrinol Metab       Date:  2015-01       Impact factor: 1.634

2.  Familial dysalbuminaemic hyperthyroxinaemia.

Authors:  S J Fleming; G F Applegate; C G Beardwell
Journal:  Postgrad Med J       Date:  1987-04       Impact factor: 2.401

Review 3.  Euthyroid hyperthyroxinemia.

Authors:  R Rajatanavin; L E Braverman
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

4.  Molecular genetics of human serum albumin: restriction enzyme fragment length polymorphisms and analbuminemia.

Authors:  J C Murray; C M Demopulos; R M Lawn; A G Motulsky
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

5.  Hyperthyroxinemia associated with high thyroxine binding to albumin in euthyroid subjects.

Authors:  P De Nayer; P Malvaux
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

6.  Role of serum carrier proteins in the peripheral metabolism and tissue distribution of thyroid hormones in familial dysalbuminemic hyperthyroxinemia and congenital elevation of thyroxine-binding globulin.

Authors:  R Bianchi; G Iervasi; A Pilo; F Vitek; M Ferdeghini; F Cazzuola; G Giraudi
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

7.  A four generation study of familial dysalbuminemic hyperthyroxinemia: diagnosis in the presence of an acquired excess of thyroxine-binding globulin.

Authors:  P P Yeo; Y Yabu; J R Etzkorn; R Rajatanavin; L E Braverman; S H Ingbar
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

8.  Homozygous Mutation in Human Serum Albumin and Its Implication on Thyroid Tests.

Authors:  Mizuho S Mimoto; Anara Karaca; Neal Scherberg; Alexandra M Dumitrescu; Samuel Refetoff
Journal:  Thyroid       Date:  2018-05-24       Impact factor: 6.568

9.  Congenital hypothyroidism and partial thyroid hormone unresponsiveness of the pituitary in a patient with congenital thyroxine binding albumin elevation.

Authors:  S L Drop; E P Krenning; R Docter; S M de Muinck Keizer-Schrama; T J Visser; G Hennemann
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

10.  A new type of albumin with predominantly increased binding affinity for 3,3',5-triiodothyronine in a patient with Graves' disease.

Authors:  Y Yabu; K Miyai; A Kobayashi; K Miki; K Doi; J Takamatsu; T Mozai; F Matsuzuka; K Kuma
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.